The #1 Insider Stock for 2026

Over the past decade, investing in biotech stocks with insider buying has tripled the S&P 500’s return.  

Tandem Diabetes Care (Nasdaq: TNDM) and Exscientia PLC - now a subsidiary of Recursion Pharmaceuticals (Nasdaq: RXRX) – are prime examples of some I’ve recommended. The former was a particularly big winner, allowing my readers to lock in up to a 1,795% gain in less than one year. 

Needless to say, I’m bullish on the industry. 

And I’ve recently found a new biotech company focusing on autoimmune disease… one of the biggest segments in healthcare.  

See, autoimmune diseases are a unique problem in medicine. They aren’t caused by a virus or bacterial infection, at least not directly. They’re caused by a given gene being activated or deactivated (sometimes by a virus or bacteria), which causes the body’s immune system to attack healthy tissues.  

Much like cancer, there’s no foreign intruder within the body – it’s a person’s own body going wrong. The family of diseases includes conditions like psoriasis, celiac disease, diabetes, POTS, and many, many more. In all, over 50 million Americans suffer from autoimmune diseases and, unfortunately, that number is growing.  

Over the past 40 years, the number of people with Type 1 diabetes has doubled. Celiac disease has increased fivefold over the same four-decade span.  

Drugs used to treat autoimmune diseases are some of the most successful drugs on the market. Take Merck’s Keytruda, for instance. It’s used to treat various autoimmune cancers and is the bestselling drug on the market. Humira is another prime example. It’s the third–best-selling drug on the market and is used to treat rheumatoid arthritis, another major autoimmune condition. 

The company that most recently caught my attention is focused entirely on autoimmune disease and the profit potential of that market. It’s called Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH).   

Unique Diseases in Need of Unique Treatments

Based in Victoria, Canada, Aurinia is focused on developing and commercializing therapies for diseases with unmet treatment needs.  

It’s best known for Lupkynis, a drug designed to treat active lupus nephritis. It’s a debilitating autoimmune kidney condition. The immune systems of people with the disease attack healthy kidney tissue and can cause kidney damage or failure, heart disease, and stroke, along with more minor symptoms, like high blood pressure, fatigue, and fever. 

The result for patients is 45 times the risk of kidney failure. In fact, 10% to 30% of patients with the condition experience kidney failure within 15 years of diagnosis. They also have three times the risk of premature death, twice the hospitalization rate of ordinary people, twice the length of hospital stays, and five times the medical costs if kidney failure develops

The normal treatments can keep the condition under control, but not as well as you might hope. Only 22.5% of patients treated with the standard drugs have a response and relief from the symptoms of their disease. Lupkynis nearly doubles that: 40.8% of patients treated with it have a full response and relief.  

A treatment that doubles the efficacy of the standard of care is a game changer. And this one already has FDA approval. It’s had approval since January 22, 2021, and is the first oral therapy approved for treating active lupus nephritis in adults.  

Traditional treatments for active lupus nephritis broadly suppress the immune system to prevent it from attacking the kidneys. However, their efficacy is limited. Lupkynis can also be combined with traditional drugs for a more targeted effect, achieving a better outcome faster.  

And Aurinia’s sales figures continue to show that the drug is working and gaining wider acceptance in real-world use. Since Lupkynis came to market, adoption has steadily expanded, driving healthy double-digit revenue growth as more nephrologists incorporate the therapy into standard lupus nephritis treatment.

At the same time, Aurinia is laying the groundwork for its next phase of growth. The company has begun advancing a new autoimmune disease candidate, aimed at extending its reach beyond lupus nephritis and building on its expertise in immunology.

Insiders are piling in. But the good news for Aurinia’s bottom line doesn’t end there… 

A $10 Million Vote of Confidence

Let’s address the most important signal first.

Over a relatively short period, a group of Aurinia insiders collectively purchased more than $10 million worth of company shares in the open market. For a company with a market capitalization hovering around the $1 billion level, that is a meaningful commitment of personal capital – not a symbolic gesture.

Those purchases came from board members Jill Leversage, Jeff Bailey, and David Jayne, all of whom added to their positions within the same general timeframe. When multiple insiders buy in close succession, it often carries more weight than a single transaction. It suggests shared conviction, not coincidence.

Insiders sell stock for many reasons. They buy for far fewer – and usually only when they believe the market is underestimating what lies ahead.

Why Insiders May Be Acting with Confidence

Aurinia’s operating performance helps explain why that confidence may be warranted.

The company’s lead therapy continues to generate growing sales as adoption expands in real-world clinical settings. Revenue has been trending higher year over year, reflecting steady uptake rather than a one-off surge – an important distinction in biotechnology.

At the same time, Aurinia has shown progress toward operating sustainability. Unlike many young biotech companies that remain deeply unprofitable for extended periods, Aurinia has demonstrated the ability to translate revenue growth into improving earnings while still investing in its pipeline.

The balance sheet adds another layer of support. Aurinia maintains a sizable cash position relative to its size, providing flexibility to fund ongoing commercialization efforts and advance additional autoimmune programs without relying heavily on near-term financing. In an industry where dilution is often the cost of survival, that kind of financial footing stands out.

Put it all together – growing sales, improving operating leverage, and a solid cash position – and the insider activity begins to make more sense.

All of this information is publicly available. What outside investors cannot see with the same clarity is what insiders observe firsthand: prescribing trends, payer dynamics, pipeline progress, and how the business is evolving beneath the surface.

When insiders commit this level of personal capital in a company that is strengthening operationally, it tends to be one of the clearest signals that leadership believes the market has not yet caught up to the underlying story.

Action to Take: Buy Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH) at market. Set a 25% trailing stop to protect your principal and your profits.